Profile data is unavailable for this security.
About the company
Zhejiang Ausun Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development (R&D), production and sales of specialty bulk pharmaceutical chemicals (BPCs) and pharmaceutical intermediates. The Company also provides custom manufacturing, R&D services, and other services to customers. The specialty API and intermediates business provides global generic drug manufacturers with services including non-patent infringement process design, process development and research, pharmaceutical regulatory filing, and cGMP standard commercial production for drugs with expired or soon-to-expire patents. CRO/CDMO/CMO business provides domestic and foreign pharmaceutical companies with new drug process development and product preparation from preclinical, clinical, to commercialization stages. The formulation business develops specialty formulations. The innovative drug business includes investing in new drug companies, and introducing and developing new drugs.
- Revenue in CNY (TTM)751.12m
- Net income in CNY184.84m
- Incorporated2010
- Employees1.22k
- LocationZhejiang Ausun Pharmaceutical Co LtdNo. 5, Donghai 4th Avenue, Linhai ParkChemcial Raw Materials Pharmaceutical BaTAIZHOU 317016ChinaCHN
- Phone+86 57 685589367
- Fax+86 57 685589367
- Websitehttps://www.ausunpharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cisen Pharmaceutical Co Ltd | 3.56bn | 492.80m | 7.76bn | 3.30k | 15.81 | 1.26 | -- | 2.18 | 1.08 | 1.08 | 7.84 | 13.59 | 0.472 | 2.10 | 5.34 | 1,079,074.00 | 6.58 | 6.51 | 8.12 | 8.07 | 53.70 | 55.92 | 13.94 | 10.84 | 3.48 | -- | 0.0069 | 37.16 | -10.77 | -0.6464 | -2.38 | -0.2215 | -0.3051 | 10.42 |
| China Animal Husbandry Industry Co., Ltd | 6.28bn | 214.44m | 7.83bn | 4.30k | 36.52 | 1.37 | -- | 1.25 | 0.21 | 0.21 | 6.15 | 5.60 | 0.6863 | 5.30 | 4.19 | 1,461,064.00 | 2.32 | 5.25 | 3.37 | 7.48 | 15.59 | 22.15 | 3.38 | 7.31 | 1.62 | -- | 0.1625 | 31.16 | 11.30 | 7.79 | -82.41 | -22.24 | -0.0699 | -21.83 |
| Zhejiang Ausun Pharmaceutical Co Ltd | 751.12m | 184.84m | 7.97bn | 1.22k | 42.83 | 3.40 | -- | 10.61 | 0.2241 | 0.2241 | 0.8963 | 2.83 | 0.2472 | 0.9248 | 3.00 | 616,180.10 | 6.08 | 8.91 | 7.77 | 12.10 | 51.51 | 53.44 | 24.61 | 27.68 | 2.17 | -- | 0.1383 | 27.35 | -2.63 | 20.90 | -18.55 | 29.68 | 17.53 | 43.79 |
| Guangxi Wuzhou Zhongheng Group Co Ltd | 2.29bn | -363.56m | 8.06bn | 2.97k | -- | 1.39 | -- | 3.51 | -0.1112 | -0.1112 | 0.7189 | 1.82 | 0.204 | 2.09 | 3.30 | 771,487.60 | -4.90 | -0.1745 | -7.79 | -0.2739 | 34.13 | 64.36 | -24.05 | -0.6631 | 2.01 | -5.26 | 0.2563 | 69.54 | -26.67 | -9.85 | -547.14 | -- | 4.41 | -- |
| Changchun BCHT Biotechnology Co | 677.51m | -170.53m | 8.07bn | 1.27k | -- | 2.04 | -- | 11.92 | -0.4124 | -0.4124 | 1.64 | 9.57 | 0.1288 | 0.7183 | 0.4756 | 531,801.10 | -3.24 | 8.14 | -4.12 | 10.19 | 77.22 | 85.58 | -25.17 | 23.29 | 1.20 | -8.89 | 0.0696 | 14.91 | -32.64 | 4.73 | -53.67 | 0.9824 | 33.40 | -- |
| Sichuan Huiyu Pharmaceutical Co Ltd | 984.29m | 47.23m | 8.13bn | 1.38k | 172.20 | 2.18 | -- | 8.26 | 0.1115 | 0.1115 | 2.32 | 8.81 | 0.1983 | 0.9536 | 14.36 | 712,220.30 | 0.8073 | 8.62 | 1.04 | 10.46 | 80.54 | 88.41 | 4.07 | 22.26 | 2.63 | -- | 0.1185 | 24.48 | 18.05 | 9.13 | 132.78 | 12.96 | 3.11 | -- |
| Jiangsu Kanion Pharmaceutical Co., Ltd. | 3.13bn | 234.36m | 8.16bn | 6.13k | 34.84 | 1.73 | -- | 2.61 | 0.4136 | 0.4136 | 5.50 | 8.33 | 0.459 | 2.03 | 5.49 | 510,570.90 | 3.29 | 5.72 | 4.42 | 8.14 | 67.90 | 72.85 | 7.18 | 9.42 | 1.73 | 47.38 | 0.0006 | 18.39 | -19.86 | -3.11 | -15.58 | -5.02 | -0.5518 | -- |
| Nanjing Vazyme Biotech Co Ltd | 1.34bn | -29.64m | 8.26bn | 2.87k | -- | 2.15 | -- | 6.15 | -0.0817 | -0.0817 | 3.98 | 9.66 | 0.2715 | 1.10 | 2.75 | 468,919.20 | -0.6649 | 9.69 | -0.8034 | 11.88 | 68.89 | 69.81 | -2.45 | 20.70 | 3.34 | -- | 0.1832 | 35.88 | 7.15 | 38.71 | 74.50 | -- | 30.38 | -- |
| Holder | Shares | % Held |
|---|---|---|
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 3.84m | 0.46% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 2.34m | 0.28% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 2.26m | 0.27% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 2.05m | 0.25% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 835.87k | 0.10% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 724.81k | 0.09% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2025 | 424.20k | 0.05% |
| Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 2025 | 413.15k | 0.05% |
| SWS MU Fund Management Co., Ltd.as of 30 Jun 2025 | 140.00k | 0.02% |
| China Fund Management Co., Ltd.as of 30 Jun 2025 | 124.20k | 0.02% |
